Background {#Sec1}
==========

Respiratory distress occurs in 7% of newborn infants and is increasingly common even in late preterm births \[[@CR1]\]. Respiratory distress syndromes and infections are represented in approximately half of all cases of preterm infants \[[@CR1]\]. Despite varied causes, the goals of managing respiratory distress include maintaining airway patency and providing respiratory support to deliver oxygen and remove carbon dioxide. In severe respiratory distress, these goals are often achieved through mechanical ventilation \[[@CR2]\]. Invasive mechanical ventilation (IMV) increases survival in preterm infants with severe respiratory distress syndrome (RDS) \[[@CR3]\]. However, IMV is associated with bronchopulmonary dysplasia (BPD) and impaired neurodevelopmental outcomes in preterm infants \[[@CR3], [@CR4]\]. Consequently, in recent years, several methods of noninvasive ventilation, including nasal continuous positive airway pressure (nCPAP), biphasic NCPAP (BP-CPAP), nasal intermittent positive-pressure ventilation, and high-flow nasal cannula, have been used with the hopes of preventing endotracheal mechanical ventilation and BPD \[[@CR5]\]. Unfortunately, clinical studies have shown that up to 38--42% of very low birth weight infants experience treatment failure and require IMV \[[@CR6], [@CR7]\]. Moreover, although nCPAP is increasingly used, BPD rates have not declined \[[@CR3], [@CR8]\]. High-frequency ventilation is considered a gentler form of IMV with superior ventilation capability \[[@CR9]\]. Applied noninvasive high-frequency oscillatory ventilation (nHFOV) may combine the benefits of nCPAP and high-frequency ventilation, which include the absence of ventilator-patient asynchrony and high efficacy in removing carbon dioxide (CO~2~) \[[@CR10]\]. nHFOV is already used in European neonatal intensive care units despite scarce evidence to support the routine use of nHFOV \[[@CR11]\]. Reviews of observational studies show an advantage with nHFOV for CO~2~ clearance in preterm infants treated for respiratory distress syndrome \[[@CR12]--[@CR14]\]. However, clinical trials could not demonstrate increased carbon dioxide clearance when applying nHFOV versus nCPAP \[[@CR15], [@CR16]\]. Because of the conflicting findings from reviews of observational studies and randomized trials, we have conducted a comprehensive systematic review evaluating all evidence by collecting data from randomized trials and prospective cohort studies.

Methods {#Sec2}
=======

Study identification and selection {#Sec3}
----------------------------------

This systematic review was conducted and is reported according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR17]\]. Electronic searches were performed in multiple databases, including PubMed, EMBASE, the Cochrane Controlled Trials Register, the Cochrane Library, Google Scholar, VIP, and Google, for relevant articles published from inception of the databases up to January 2019. The bibliographies of all potentially relevant articles were manually searched to identify any additional articles of relevance. No language restriction was applied. In addition, experts in the field were contacted to identify any ongoing or unpublished trials, although no studies were identified by this strategy. The protocol of this systematic review was registered before the literature search in PROSPERO (Prospero2016 CRD42016053475).

Eligibility criteria {#Sec4}
--------------------

For inclusion, a study had to meet the following criteria: 1) it was a randomized controlled trial or crossover trial for evaluating interventions with a temporary effect; 2) preterm infants were randomized to receive respiratory support with nHFOV vs nCPAP/BP-CPAP; and 3) it reported more than one of the following outcome parameters: partial pressure of carbon dioxide (pCO~2~) levels, ΔpCO2 (variation difference of each group before crossover in randomized controlled crossover trials), and intubation. Exclusion criteria were as follows: a) non-clinical studies (experimental and basic studies); b) observational or retrospective studies; c) duplicate reports, secondary or post hoc analyses of the same study population; and d) studies with a lack of sufficient information on baseline, primary or secondary outcome data.

Assessment of the risk of bias {#Sec5}
------------------------------

Two reviewers (Zhang and Li) independently assessed the risk of bias of individual studies and the bias domains across studies using the Cochrane collaboration tool \[[@CR18]\]. All discrepancies were resolved by discussion and consensus. The studies were rated to be at high risk of bias, low risk of bias, or unclear risk of bias based on sequence generation, concealment of allocation, blinding of participants/parents and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting.

Data collection {#Sec6}
---------------

For each study, data were extracted independently by two reviewers (Zhang and Li) using a predesigned form. Any differences and disagreements in the collected data were discussed and resolved by consensus. Details of methodological quality, study design, analysis, and results were noted. For each outcome, the numeric results, the statistical methods used, and the *P* value were recorded. For randomized controlled crossover trials, because of carry-over, we only included data from the first stage for analysis. We contacted authors of the original reports to obtain further details when information regarding any of the above information was unclear.

Statistical analysis {#Sec7}
--------------------

The statistical analyses were performed by the Mantel-Haenszel method (fixed-effect model) or the DerSimonian and Laird method (random-effect model) using the Review Manager meta-analysis software (version 5.3, 2012; The Cochrane Collaboration, Copenhagen, Denmark). Treatment effect estimates for all trials were calculated and expressed as typical relative risk (RR) for dichotomous outcomes and weighted mean difference (WMD) for continuous outcomes, all with a 95% confidence interval. The between-trial presence of heterogeneity among the recorded treatment effects was analysed by the χ2 test for heterogeneity and the I^2^ statistic, which expresses the proportion of heterogeneity that cannot be explained by chance. Heterogeneity was deemed significant when the corresponding *P* value was \< 0.1 or when the I^2^ percentage was \> 50, at which point the random-effect model was used. Otherwise, a fixed-effect model was applied \[[@CR19]\]. Subgroup analyses or sensitivity analyses were carried out to assess the source of heterogeneity. When more than 10 articles were included, the presence of publication bias was assessed and displayed through a funnel plot.

Results {#Sec8}
=======

Study selection, description and assessment {#Sec9}
-------------------------------------------

The search strategy resulted in 286 potentially relevant citations. The PRISMA flow diagram (Fig. [1](#Fig1){ref-type="fig"}) summarizes the process of the literature search and study selection. After screening the titles and abstracts, we read 26 full-text articles or abstracts and assessed them for eligibility. Eight RCTs \[[@CR16], [@CR20]--[@CR26]\] comprising 463 participants met the inclusion criteria. Overall, 6 trials \[[@CR16], [@CR20]--[@CR22], [@CR25], [@CR26]\] of nHFOV vs nCPAP as respiratory support in preterm infants included 359 infants, and 2 trials \[[@CR22], [@CR24]\] of nHFOV vs BP-CPAP as respiratory support included 104 infants.Fig. 1A PRISMA flow chart for the selection of eligible studies

Characteristics of the included studies {#Sec10}
---------------------------------------

The 8 RCTs selected for analysis included a total of 463 participants (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}) \[[@CR16], [@CR20]--[@CR26]\]. The publication dates of the RCTs ranged from 2016 to 2018. The nHFOV group vs nCPAP/BP-CPAP group were well-matched; the birth weight and gestational age did not differ significantly. Other aspects of respiratory treatment, including the resuscitation devices used and the criteria for using antenatal glucocorticoids as well as surfactant, were adequately described in the studies and conformed to current international guidelines. The incidence of neonatal respiratory distress syndrome (diagnosed based on respiratory symptoms and corresponding X-ray changes) was comparable between the nHFOV group and the nCPAP/BP-CPAP group.Table 1Characteristics of 8 RCTs and baseline characteristics of patientsStudyStudy designGroupNMale (n)GA (wk)BW (g)Antenatal steroidSurfactant (n)Caffeine (n)Bottino 2018 \[[@CR20]\]Randomized controlled crossover trialnHFOV15NA\< 32\< 1500NA1515nCPAP15NA\< 32\< 1500NA1515Klotz 2017 \[[@CR16]\]Randomized controlled crossover trialnHFOV13226.1 (2.2)\*814.2 (208.2)\*131313nCPAP13927.2 (2.0)\*1083.5 (359.1)\*131313Lou 2017 \[[@CR21]\]Randomized controlled trialnHFOV342432.5 (1.3)\*1790 (350)\*1334NAnCPAP312232.4 (1.4)\*1850 (410)\*1221NALou 2018 \[[@CR22]\]Randomized controlled trialnHFOV331833.5 (1.5)\*1790 (330)\*1233NABPCPAP321734.2 (1.6)\*1840 (420)\*1132NAMalakian 2018 \[[@CR23]\]Randomized controlled trialnHFOV632831.08 (2.9)\*1485.5 (470)\*3621NAnCPAP612531.07 (2.8)\*1505.5 (490)\*3123NAMukerji 2017 \[[@CR24]\]Randomized controlled trialnHFOV16126.1 (1.3)\*831.9 (150.1)\*1210NABPCPAP23226.5 (1.6)\*878.0 (198.3)\*2014NAZhu 2017 \[[@CR25]\]Randomized controlled trialnHFOV372231.7 (1.7)\*1670 (353)\*1337NAnCPAP392132.0 (1.9)\*1735 (327)\*1539NAZhu 2017 \[[@CR26]\]Randomized controlled trialnHFOV171031.7 (1.7)\*1670 (353)\*617NAnCPAP211232.0 (1.9)\*1735 (327)\*821NA*NA* Not Applicated, *BW*: Birth weight, \*means ±SDTable 2Interventions used in the 7 RCTsStudyType of interventionVentilator type/ InterfaceVentilator parameter settingFailure of interventionTargeted SpO2Bottino 2018 \[[@CR20]\]Primary respiratory support/\
Following extubationnHFOV: Medin, Olching,\
Germany;\
nCPAP:\
Interface: Short binasal prongsnHFOV: Flow:7\~10 L/min, Frequency: 10 Hz, Amplitude: set interval 10, I: E:1:1.\
nCPAP:NA90\~95%Klotz 2017 \[[@CR16]\]Backup ventilatory support/\
Primary respiratory supportnHFOV/nCPAP: Sophie, Stephan, Gaggenbach, Germany; Leoni plus,\
Heinen+Löwenstein, Bad Ems, Germany\
Interface: binasal prongs or nasal masksnHFOV: Frequency: 10 Hz,\
Amplitude: was set to achieve clearly visible oscillations of the chest,\
MAP: nHFOV and nCPAP were\
set at the level equal.More than two episodes of apnea\
or bradycardia per hour; respiratory acidosis with a pH \< 7.10; or FiO2 \> 0.6 to maintain a\
SpO2 \> 86%; hypercapnia with pCO2 \> 70 mmHg.86\~96%Lou 2017 \[[@CR21]\]Respiratory support after extubationnHFOV: SLEbaby5000,\
Germany.\
nCPAP: Stephan, Germany.\
Interface: Short binasal prongsnHFOV: FiO~2~: 0.35\~0.40, Frequency: 6\~12 Hz, MAP: 5\~7 cmH2O, Amplitude: is 2 to 3 times that of MAP, specifically based on visible oscillations of the chest.\
nCPAP: FiO~2~: 0.30\~0.40, PEEP: 4\~6 cmH2O, Flow: 8\~10 L/min.More than 4 episodes of apnea per day, or saturation (SpO2) of \< 85%, or paO~2~ \< 50 mmHg, or pCO~2~ \> 60 mm\
Hg.90\~95%Lou 2018 \[[@CR22]\]Primary respiratory supportnHFOV: SLEbaby5000,\
Germany;\
BP-CPAP: Fabian, Swiss.\
Interface: Short binasal prongsnHFOV: FiO~2~: 0.30\~0.40, Frequency: 6\~12 Hz, MAP: 6\~12 cmH2O, Amplitude: is 2 to 3 times that of MAP, specifically based on visible oscillations of the chest.\
BP-CPAP: FiO~2~: 0.30\~0.40, lower/higher PEEP: 5/12\~15 cmH2O.More than 4 episodes of apnea per day, or when FIO~2~ \> 0.5, saturation (SpO2) of \< 85%, or paO~2~ \< 50 mmHg, or pCO~2~ \> 60 mm\
Hg.90\~95%Malakian 2018 \[[@CR23]\]Primary respiratory supportnHFOV: Medin, Olching,\
Germany;\
nCPAP: Infant Flow-driver device\
Interface: Short binasal prongsnHFOV: MAP: 4\~8 cmH~2~O, Frequency: 5 Hz, Amplitude: MAP: 3 cmH~2~O, FiO2:0.4\~0.6.\
nCPAP: PEEP: 4\~8 cmH2O, FiO2:0.4\~0.6at least one of the following: pH ≤7.20 and PaCO2 ≥ 60 mmHg, PaO2 ≤ 50 mmHg with a fraction of inspired oxygen of ≥0.6 or recurrent\
apnea with ≥3 episodes per hour associated with bradycardia, or a single episode of apnea that\
required bag-and-mask ventilation≥ 90%Mukerji 2017 \[[@CR24]\]Following CPAP failurenHFOV: Drager VN500, Lubeck, Germany;\
BP-CPAP: SiPAP, Carefusion, USA.\
Interface: Short binasal prongs or nasal masksnHFOV: FiO~2~: \< 0.6, Frequency: 6\~14 Hz, MAP: 8\~10 cmH~2~O, Amplitude: were adjusted to achieve palpable/visible chest vibrations.\
BP-CPAP: FiO~2~: \< 0.6, lower/higher PEEP: 5\~7/8\~10 cmH~2~O.Intubation 7 days post randomization, Not specifically described.90\~95%Zhu 2017 \[[@CR25]\]Primary respiratory supportnHFOV: Medin, Olching,\
Germany;\
nCPAP: Stephan, Germany\
Interface: Binasal prongsnHFOV: Flow:8\~12 L/min, Frequency: 6\~12 Hz, Amplitude: 7\~10.\
nCPAP: PEEP: 6 cmH2O.PaCO2 \> 60 mmHg with pH \< 7.20, or more than 3 episodes of apnea per hour\
that required bag and mask ventilation, or hypoxia (FiO2 \> 0.5 with PaO2 \< 50 mmHg), or pulmonary hemorrhage.90\~94%Zhu 2017 \[[@CR26]\]Primary respiratory supportnHFOV: Medin, Olching,\
Germany;\
nCPAP: Fabian, Swiss\
Interface: Binasal prongsnHFOV: Flow:8\~12 L/min, Frequency: 6\~12 Hz, Amplitude: 6\~10, FiO2:0.25\~0.6.\
nCPAP: PEEP: 5\~8 cmH2O, FiO~2~:0.25\~0.6FiO2 \> 0.5 with PaO2 \< 50 mmHg; PaCO2 \> 60 mmHg with pH \< 7.20; Frequent apnea episode (\> 3/h)88\~93%*nHFOV* noninvasive high-frequency oscillatory ventilation, *nCPAP* nasal continuous positive airway pressure, *BP-CPAP* biphasic continuous positive airway pressure, *MAP* Mean airway pressure, *PEEP* Positive end expiratory pressure, *FiO*~*2*~: fraction of inspired oxygenTable 3Outcomes measured in the 7 RCTsStudyGrouppCO2 levels\*△pCO2\*IntubationBottino 2018 \[[@CR20]\]nHFOV46.6 (7.5)− 3.4 (7.77)0/15nCPAP49.9 (6.7)1.4 (7.31)0/15Klotz 2017 \[[@CR16]\]nHFOV54.8 (14.6)3.6 (12.66)0/13nCPAP49 (8.1)−1 (7.01)0/13Lou 2017 \[[@CR21]\]nHFOV35.1 (7.8)−1.4 (7.85)5/34nCPAP40.6 (7.8)2.4 (7.24)12/31Lou 2018 \[[@CR22]\]nHFOV41.5 (6.3)−13 (7.43)9/33BP-CPAP50.5 (6.5)−3.1 (7.0)10/32Malakian 2018 \[[@CR23]\]nHFOV4/63nCPAP9/61Mukerji 2017 \[[@CR24]\]nHFOVNANA6/16BP-CPAPNANA15/23Zhu 2017 \[[@CR25]\]nHFOVNANA9/37nCPAPNANA22/39Zhu 2017 \[[@CR26]\]nHFOV43.7 (5.6)−12.1 (5.08)4/17nCPAP48 (4.7)−6.3 (4.29)12/21*NA* Not Applicated, \* means ± SD, pCO2 levels refers to Post nHFOV or nCPAP/BP-CPAP

Risk of bias within individual studies {#Sec11}
--------------------------------------

The risk of bias assessment for the included RCTs \[[@CR16], [@CR20]--[@CR26]\] is reported in Table [4](#Tab4){ref-type="table"}. Two trials were randomized controlled crossover trials \[[@CR16], [@CR20]\]. Most studies had a moderate to high risk of bias. Most bias stemmed from the blinding of the participants and personnel and the outcome assessments. The method of randomization was determined to be adequate in all studies. Four studies were found to have adequate concealment of allocation (Table [4](#Tab4){ref-type="table"}).Table 4Risk of Bias Assessment for Included Randomized Clinical TrialsSourceBiasSelectionPerformance:\
Blinding of Participant\
and PersonnelDetection:\
Blinding of Outcome\
AssessmentAttrition:\
Incomplete\
Outcome DataSelective\
ReportingOther\
SourcesOverallRandom\
Sequence\
GenerationAllocation\
ConcealmentBottino 2018 \[[@CR20]\]Low riskLow riskHigh riskHigh riskLow riskLow riskUnclear riskHigh riskKlotz 2017 \[[@CR16]\]Low riskLow riskHigh riskHigh riskLow riskUnclear riskUnclear riskHigh riskLou 2017 \[[@CR21]\]Low riskUnclear riskHigh riskHigh riskLow riskUnclear riskUnclear riskHigh riskLou 2018 \[[@CR22]\]Low riskUnclear riskHigh riskHigh riskLow riskUnclear riskUnclear riskHigh riskMalakian 2018 \[[@CR23]\]Low riskUnclear riskHigh riskHigh riskHigh riskUnclear riskUnclear riskHigh riskMukerji 2017 \[[@CR24]\]Low riskLow riskHigh riskHigh riskHigh riskHigh riskUnclear riskHigh riskZhu 2017 \[[@CR25]\]Low riskLow riskUnclear riskUnclear riskLow riskUnclear riskUnclear riskModerate riskZhu 2017 \[[@CR26]\]Low riskUnclear riskUnclear riskUnclear riskLow riskUnclear riskUnclear riskModerate risk

Systematic review of the findings from the collected results {#Sec12}
------------------------------------------------------------

*pCO2 levels, ΔpCO2, and intubation.* Five trials enrolling 224 preterm infants reported pCO2 levels. Meta-analysis indicated that nHFOV significantly reduced pCO2 in preterm infants compared with nCPAP/BP-CPAP, including pCO2 levels (WMD = − 4.61, 95% CI -7.94 to − 1.28, I^2^ = 67%, *P* = 0.007) after respiratory support and ΔpCO2 (WMD = − 4.89, 95% CI -8.36 to − 1.42, I2 = 70%, *P* = 0.006) before and after respiratory support (Fig. [2](#Fig2){ref-type="fig"}). Eight trials enrolling 283 preterm infants reported on the rates of intubation. Meta-analysis indicated that nHFOV was associated with a lower likelihood of intubation for mechanical ventilation within 7 days than nCPAP/BP-CPAP was (RR = 0.50, 95% CI 0.36 to 0.70, I2 = 0%, *P* \< 0.0001) (Fig. [3](#Fig3){ref-type="fig"}). A sensitivity analysis restricted to studies clearly stating the positive results \[[@CR22], [@CR25]\] showed similar results (RR = 0.57, 95% CI 0.38 to 0.87, I^2^ = 0%, *P* = 0.009).Fig. 2Meta-analysis of the effect of CO~2~ removal with the use of nHFOV or nCPAP/BP-CPAPFig. 3Meta-analysis of rate of intubation with the use of nHFOV or nCPAP/BP-CPAP

Discussion {#Sec13}
==========

This meta-analysis identified 8 randomized trials with 463 premature infants that compared respiratory support with nHFOV to that with nCPAP/BP-CPAP in preterm infants. The results of this systematic review of available RCTs show that in preterm infants, the use of nHFOV rather than nCPAP/BP-CPAP was beneficial in terms of improved CO~2~ elimination and a reduced risk of intubation for mechanical ventilation.

The quality of systematic reviews depends on the quality of the studies included. We evaluated the risk of bias in the RCTs analysed. Methodological issues may affect the study quality. We scrutinized the selected studies for good methodologic quality using strict quality assessment criteria \[[@CR27]\]. The present review, to the best of our knowledge, is the first meta-analysis of RCTs reporting on the use of nHFOV compared with nCPAP/BP-CPAP as respiratory support in preterm infants. As a new noninvasive respiratory support method; there are relatively few prospective studies on nHFOV for preterm infants, and most studies are retrospective studies \[[@CR12]--[@CR14]\]. Most bench studies have clarified the effectiveness of nHFOV in promoting carbon dioxide removal from intrinsic mechanical properties \[[@CR28]--[@CR30]\], and nHFOV is superior to NIPPV in lung CO~2~ elimination \[[@CR31]\]. Noninvasive interfaces affect tidal volume (Tv) and DCO~2~, and smaller cannulae result in lower tidal volume (Tv) reaching the distal airways and less CO~2~ elimination \[[@CR28], [@CR29]\]. Using lower frequency and higher amplitude in the nHFOV device increases Tv and promotes CO~2~ removal \[[@CR30]\]. Similar to our meta-analysis, most retrospective studies found that nHFOV can effectively remove CO~2~. Van der Hoeven et al. \[[@CR12]\] investigated the efficacy of nHFOV in a heterogeneous group of 21 infants with moderate respiratory insufficiency and showed that nHFOV was effective in reducing pCO~2~. Mukerji et al. \[[@CR13]\] reported that nHFOV significantly reduces the occurrences of apnoeas, bradycardias, desaturations and CO~2~ levels compared with No nHFOV. nHFOV is effective in decreasing pCO~2~ in stable premature infants who require nasal CPAP support \[[@CR14]\]. Recently, two RCTs by Rüegger et al. \[[@CR15]\] (no specific data were reported) and Klotz et al. \[[@CR16]\] showed that nHFOV fails to increase CO~2~ clearance compared with nCPAP in preterm infants; the former study mainly evaluated clinical symptom outcomes and included the paired difference in the combined number of episodes of desaturation and bradycardia during the 120-min period \[[@CR15]\], and the latter study enrolled some patients who already had low CO~2~ \[[@CR16]\]. Reducing CO~2~ levels is beneficial for severe hypercapnia, which may be harmful to maintaining normal CO~2~ levels \[[@CR32]\]. Moreover, invasive neonatal ventilators (Sophie, Stephan, Gaggenbach, Germany; Leoni plus, Heinen+Löwenstein, Bad Ems, Germany) can be used to make an nHFOV mode through bi-nasal prongs or nasal masks with the frequency set to 10 Hz \[[@CR16]\]. Experimental and clinical observational data using nHFOV devices other than the CNO device (Medin, CNO) suggest the need for much higher amplitudes at a frequency of 10 Hz, especially for low-compliant lung disease, to have a clinically relevant effect on pCO~2~ \[[@CR33]\]. Compared with the dedicated noninvasive high-frequency generator (Medin, CNO), nondedicated high-frequency ventilators may be prone to air leakage or may not reach the set parameters in the airway due to lack of air leakage compensation because there is no pressure sensor. Wang et al. \[[@CR34]\] reported that the effect of a nondedicated high-frequency ventilator (SLE5000) is similar to that of a dedicated high-frequency noninvasive generator (Medin, CNO) in clearing carbon dioxide and requiring intubation; however, the mean airway pressure of a nondedicated noninvasive high-frequency ventilator (SLE5000) (10(9,11)) is significantly higher than that of a dedicated high-frequency generator (Medin, CNO) (5(5,7)) \[[@CR3]\]. In addition, a bench study showed that the optimal frequency for CO~2~ removal was 8 Hz \[[@CR31]\]. In addition to the results from model studies and retrospective studies, our meta-analysis that was based on randomized controlled trials also confirmed that nHFOV can significantly remove CO~2~. Although removing CO~2~ is a weak outcome and is not directly related to major clinical outcomes, infants who fail to respond to nCPAP/BP-CPAP and retain CO~2~ can avoid intubation altogether with nHFOV. The role of nHFOV in removing carbon dioxide seems undisputed, and we should pay more attention to the effectiveness of nHFOV in different lung diseases and the long-term effects of nHFOV, such as BPD, IVH, NEC, infancy respiratory function and neurodevelopmental outcomes.

Although retrospective studies reported the feasibility of nHFOV in preventing intubation or facilitating extubation \[[@CR13], [@CR35]\], four RCTs did not show that noninvasive high-frequency ventilation had significant advantages in avoiding intubation compared with nCPAP/BP-CPAP \[[@CR22]--[@CR24], [@CR26]\]. However, our meta-analysis showed that noninvasive high-frequency ventilation can reduce the risk for intubation compared with nCPAP/BP-CPAP, and the finding was robust to sensitivity analysis. It is important to note that when trials mixed patients of different mechanical risks, inappropriate parameter settings of nHFOV may be useless. Therefore, lung mechanics may vary in different patients and in different moments during the disease course, and this may require adjustments of various parameters \[[@CR31]\]. Since CO~2~ elimination under nHFOV is provided in the upper airway dead-space \[[@CR31]\], it is probably unnecessary to increase ΔP to achieve a visible chest oscillation for less severely ill infants (such as those affected by RDS or TTN) \[[@CR33]\]. However, for patients with BPD or acute-on-chronic respiratory failure, NHFOV with real oscillators at high amplitudes is possibly useful to avoid invasive ventilation \[[@CR33]\]. This factor deserves targeted trials, which are rare and difficult to perform. Fortunately, two multi-centre trials (NCT03181958, NCT03099694) are presently ongoing to draw objective conclusions. To optimize respiratory support for different patients and different moments during the disease course, a tool to help trial designers go through explanatory and pragmatic trials is necessary \[[@CR36], [@CR37]\]. In addition, the interface may affect the ventilation effect. In vitro studies show that devices with short double prongs had the lowest resistance to flow when nCPAP was used for respiratory support \[[@CR38]\]. A bench and in vivo study showed that the amplitude of oscillation obviously decreases when the mask is used for high-frequency oscillatory ventilation \[[@CR39]\]. Two studies included in our meta-analysis used nasal masks \[[@CR16], [@CR24]\]. This may have affected the ventilation, including CO~2~ removal and intubation, in those studies.

Although 6 RCTs included in our meta-analysis reported BPD and air leak, and 5 RCTs reported IVH, because the vast majority of trials examined are small, with cross-over design and not powered for these outcomes; the population included in the RCTs is generally late preterm infants, it may affect an outcome of BPD. It is inappropriate to perform meta-analysis of these outcomes. Therefore, we believe that a large multi-centre trial is urgently needed to confirm the effect of nHFOV in extremely preterm infants and the safety of nHFOV.

Admittedly, several limitations in our meta-analysis might have affected the interpretation of the findings. The analysed trials differed in their study design and clinical characteristics of the study participants. Two of the studies we included were randomized controlled crossover trials. Although the first period of a cross-over trial is in effect a parallel group comparison, use of data from only the first period will be biased if, as is likely, the decision to do so is based on a test of carry-over \[[@CR18]\]. There was heterogeneity in the characteristics of the participants and interventions (including types and parameter settings of the noninvasive high-frequency ventilator) and a lack of a standardized assessment of intubation risk. Due to the mechanical characteristics of nHFOV, there are no trials reporting on the training of this respiratory support; thus, there is bias created by the different expertise levels of NICU personnel in using the technique. Furthermore, our meta-analysis was limited by the overall low quality of evidence and lack of robustness in higher quality trials. Publication bias could not be ruled out using a funnel plot due to a limited number of studies. Additionally, subgroup analyses based on gestational age or birth weight could not be performed due to the lack of individual patient data. Most premature infants included in this meta-analysis had a gestational age of over 30 weeks. For preterm infants under 30 weeks of age, who are severely affected by RDS and face a high risk of BPD, nHFOV may be beneficial \[[@CR40]\]. Other possible biases include: the use of different interfaces across the studies are known to impact on mechanical efficiency of all types of noninvasive ventilation and even for nHFOV \[[@CR33]\]; the measure of pCO2 by different methods (arterial, arterialised capillary and transcutaneous) in different studies may affect the results. Some studies may use venous CO2 and this should be avoided. In addition to sound design and adequate sample size, future research should not ignore populations of extremely premature infants, complex respiratory physiology and evaluating comfort \[[@CR40], [@CR41]\].

Conclusion {#Sec14}
==========

In summary, the results of our meta-analysis of RCTs suggest that nHFOV, as respiratory support in preterm infants, significantly reduces the pCO~2~ level and risk for intubation compared with nCPAP/BP-CPAP. The appropriate parameter settings for different types of noninvasive high-frequency ventilators, the effect of nHFOV in extremely preterm infants, and the long-term outcome of nHFOV need to be assessed in large trials.
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===============

 {#Sec15}

Additional file 1: Figure S1. Meta-analysis of adverse outcome with the use of nHFOV or nCPAP/BP-CPAP.
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